Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris : Review of the literature and results of a survey sent to 100 dermatologists
Plaque-type psoriasis may at times require systemic therapy. There are limited data as to whether topical calcipotriene ointment 0.005% can be used to increase the efficacy and improve the risk/benefit ratio of concurrent systemic antipsoriatic therapy. We attempt to answer this question by means of...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 1997-09, Vol.37 (3), p.S62-S68 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S68 |
|---|---|
| container_issue | 3 |
| container_start_page | S62 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 37 |
| creator | KATZ, H. I |
| description | Plaque-type psoriasis may at times require systemic therapy. There are limited data as to whether topical calcipotriene ointment 0.005% can be used to increase the efficacy and improve the risk/benefit ratio of concurrent systemic antipsoriatic therapy.
We attempt to answer this question by means of a literature review and results of a written survey that was sent to 100 international psoriasis treatment experts.
The survey was sent to academic and psoriasis treatment center-based dermatologists who treat approximately 3000 to 4000 patients with psoriasis per month. The survey requested that dermatologists relate their experience regarding the safety and efficacy of topical, systemic, and combined topical/systemic agents in psoriasis after 8 weeks of therapy.
The results of the survey support the experience in the literature regarding the favorable use of calcipotriene ointment combined with systemic therapy for the treatment of psoriasis.
Combination therapy with calcipotriene ointment and acitretin/etretinate, cyclosporine, methotrexate, or phototherapy usually enhances efficacy while improving the risk/benefit ratio by decreasing exposure to the potentially hazardous systemic agent. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_9344188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9344188</sourcerecordid><originalsourceid>FETCH-LOGICAL-p150t-14853f34e1a6f785952535b7a4d9e3a2425eb171b3fc6def9066dab2de61813b3</originalsourceid><addsrcrecordid>eNo9kEFr3DAQhU1ISDeb_oTAHJKji2RZttVbWJqksFAoyXkZ2-NEwbZUjbxl_2R_U-zuksMwDO-9b-CdJSspTJkWZVWeJyshjUhNkWVfkivmdyGEyVV5mVwaleeyqlbJv40bajtSC9F522AP8zTWuxgsjQTOjnGgMYL4JoS-Axxb2GOwbmLgA0cabAPxjQJ6Swx2XA6IgfAYcx34Hv9MlMaDJ_DsgkW2DPupf505DN_hN-0t_V2sS7a3cabFKdD_Z4F46iMvKgJPYU8H4IUcHUghoKUwYHS9e7Uc-Tq56LBn-nra6-Tl4cfz5ind_nr8ubnfpl5qEVOZV1p1KieJRVdW2uhMK12XmLeGFGZ5pqmWpaxV1xQtdUYURYt11lIhK6lqtU5ujlw_1QO1Ox_sgOGwO_U667cnHXkutAs4NpY_bZkojdBGfQCu74Zn</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris : Review of the literature and results of a survey sent to 100 dermatologists</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>KATZ, H. I</creator><creatorcontrib>KATZ, H. I</creatorcontrib><description>Plaque-type psoriasis may at times require systemic therapy. There are limited data as to whether topical calcipotriene ointment 0.005% can be used to increase the efficacy and improve the risk/benefit ratio of concurrent systemic antipsoriatic therapy.
We attempt to answer this question by means of a literature review and results of a written survey that was sent to 100 international psoriasis treatment experts.
The survey was sent to academic and psoriasis treatment center-based dermatologists who treat approximately 3000 to 4000 patients with psoriasis per month. The survey requested that dermatologists relate their experience regarding the safety and efficacy of topical, systemic, and combined topical/systemic agents in psoriasis after 8 weeks of therapy.
The results of the survey support the experience in the literature regarding the favorable use of calcipotriene ointment combined with systemic therapy for the treatment of psoriasis.
Combination therapy with calcipotriene ointment and acitretin/etretinate, cyclosporine, methotrexate, or phototherapy usually enhances efficacy while improving the risk/benefit ratio by decreasing exposure to the potentially hazardous systemic agent.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>PMID: 9344188</identifier><identifier>CODEN: JAADDB</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject><![CDATA[Acitretin - administration & dosage ; Acitretin - therapeutic use ; Administration, Topical ; Biological and medical sciences ; Calcitriol - administration & dosage ; Calcitriol - analogs & derivatives ; Calcitriol - therapeutic use ; Combined Modality Therapy ; Cyclosporine - administration & dosage ; Cyclosporine - therapeutic use ; Dermatologic Agents - administration & dosage ; Dermatologic Agents - therapeutic use ; Drug Synergism ; Drug Therapy, Combination ; Etretinate - administration & dosage ; Etretinate - therapeutic use ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - therapeutic use ; Keratolytic Agents - administration & dosage ; Keratolytic Agents - therapeutic use ; Medical sciences ; Methotrexate - administration & dosage ; Methotrexate - therapeutic use ; Ointments ; Pharmacology. Drug treatments ; Phototherapy ; Psoriasis - drug therapy ; Risk ; Safety ; Skin, nail, hair, dermoskeleton ; Treatment Outcome]]></subject><ispartof>Journal of the American Academy of Dermatology, 1997-09, Vol.37 (3), p.S62-S68</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23911,23912,25120</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2079059$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9344188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KATZ, H. I</creatorcontrib><title>Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris : Review of the literature and results of a survey sent to 100 dermatologists</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Plaque-type psoriasis may at times require systemic therapy. There are limited data as to whether topical calcipotriene ointment 0.005% can be used to increase the efficacy and improve the risk/benefit ratio of concurrent systemic antipsoriatic therapy.
We attempt to answer this question by means of a literature review and results of a written survey that was sent to 100 international psoriasis treatment experts.
The survey was sent to academic and psoriasis treatment center-based dermatologists who treat approximately 3000 to 4000 patients with psoriasis per month. The survey requested that dermatologists relate their experience regarding the safety and efficacy of topical, systemic, and combined topical/systemic agents in psoriasis after 8 weeks of therapy.
The results of the survey support the experience in the literature regarding the favorable use of calcipotriene ointment combined with systemic therapy for the treatment of psoriasis.
Combination therapy with calcipotriene ointment and acitretin/etretinate, cyclosporine, methotrexate, or phototherapy usually enhances efficacy while improving the risk/benefit ratio by decreasing exposure to the potentially hazardous systemic agent.</description><subject>Acitretin - administration & dosage</subject><subject>Acitretin - therapeutic use</subject><subject>Administration, Topical</subject><subject>Biological and medical sciences</subject><subject>Calcitriol - administration & dosage</subject><subject>Calcitriol - analogs & derivatives</subject><subject>Calcitriol - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Cyclosporine - administration & dosage</subject><subject>Cyclosporine - therapeutic use</subject><subject>Dermatologic Agents - administration & dosage</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Drug Synergism</subject><subject>Drug Therapy, Combination</subject><subject>Etretinate - administration & dosage</subject><subject>Etretinate - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Keratolytic Agents - administration & dosage</subject><subject>Keratolytic Agents - therapeutic use</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - therapeutic use</subject><subject>Ointments</subject><subject>Pharmacology. Drug treatments</subject><subject>Phototherapy</subject><subject>Psoriasis - drug therapy</subject><subject>Risk</subject><subject>Safety</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Treatment Outcome</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEFr3DAQhU1ISDeb_oTAHJKji2RZttVbWJqksFAoyXkZ2-NEwbZUjbxl_2R_U-zuksMwDO-9b-CdJSspTJkWZVWeJyshjUhNkWVfkivmdyGEyVV5mVwaleeyqlbJv40bajtSC9F522AP8zTWuxgsjQTOjnGgMYL4JoS-Axxb2GOwbmLgA0cabAPxjQJ6Swx2XA6IgfAYcx34Hv9MlMaDJ_DsgkW2DPupf505DN_hN-0t_V2sS7a3cabFKdD_Z4F46iMvKgJPYU8H4IUcHUghoKUwYHS9e7Uc-Tq56LBn-nra6-Tl4cfz5ind_nr8ubnfpl5qEVOZV1p1KieJRVdW2uhMK12XmLeGFGZ5pqmWpaxV1xQtdUYURYt11lIhK6lqtU5ujlw_1QO1Ox_sgOGwO_U667cnHXkutAs4NpY_bZkojdBGfQCu74Zn</recordid><startdate>199709</startdate><enddate>199709</enddate><creator>KATZ, H. I</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>199709</creationdate><title>Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris : Review of the literature and results of a survey sent to 100 dermatologists</title><author>KATZ, H. I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p150t-14853f34e1a6f785952535b7a4d9e3a2425eb171b3fc6def9066dab2de61813b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Acitretin - administration & dosage</topic><topic>Acitretin - therapeutic use</topic><topic>Administration, Topical</topic><topic>Biological and medical sciences</topic><topic>Calcitriol - administration & dosage</topic><topic>Calcitriol - analogs & derivatives</topic><topic>Calcitriol - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Cyclosporine - administration & dosage</topic><topic>Cyclosporine - therapeutic use</topic><topic>Dermatologic Agents - administration & dosage</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Drug Synergism</topic><topic>Drug Therapy, Combination</topic><topic>Etretinate - administration & dosage</topic><topic>Etretinate - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Keratolytic Agents - administration & dosage</topic><topic>Keratolytic Agents - therapeutic use</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - therapeutic use</topic><topic>Ointments</topic><topic>Pharmacology. Drug treatments</topic><topic>Phototherapy</topic><topic>Psoriasis - drug therapy</topic><topic>Risk</topic><topic>Safety</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KATZ, H. I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KATZ, H. I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris : Review of the literature and results of a survey sent to 100 dermatologists</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>1997-09</date><risdate>1997</risdate><volume>37</volume><issue>3</issue><spage>S62</spage><epage>S68</epage><pages>S62-S68</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><coden>JAADDB</coden><abstract>Plaque-type psoriasis may at times require systemic therapy. There are limited data as to whether topical calcipotriene ointment 0.005% can be used to increase the efficacy and improve the risk/benefit ratio of concurrent systemic antipsoriatic therapy.
We attempt to answer this question by means of a literature review and results of a written survey that was sent to 100 international psoriasis treatment experts.
The survey was sent to academic and psoriasis treatment center-based dermatologists who treat approximately 3000 to 4000 patients with psoriasis per month. The survey requested that dermatologists relate their experience regarding the safety and efficacy of topical, systemic, and combined topical/systemic agents in psoriasis after 8 weeks of therapy.
The results of the survey support the experience in the literature regarding the favorable use of calcipotriene ointment combined with systemic therapy for the treatment of psoriasis.
Combination therapy with calcipotriene ointment and acitretin/etretinate, cyclosporine, methotrexate, or phototherapy usually enhances efficacy while improving the risk/benefit ratio by decreasing exposure to the potentially hazardous systemic agent.</abstract><cop>New York, NY</cop><pub>Elsevier</pub><pmid>9344188</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 1997-09, Vol.37 (3), p.S62-S68 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_pubmed_primary_9344188 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acitretin - administration & dosage Acitretin - therapeutic use Administration, Topical Biological and medical sciences Calcitriol - administration & dosage Calcitriol - analogs & derivatives Calcitriol - therapeutic use Combined Modality Therapy Cyclosporine - administration & dosage Cyclosporine - therapeutic use Dermatologic Agents - administration & dosage Dermatologic Agents - therapeutic use Drug Synergism Drug Therapy, Combination Etretinate - administration & dosage Etretinate - therapeutic use Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Keratolytic Agents - administration & dosage Keratolytic Agents - therapeutic use Medical sciences Methotrexate - administration & dosage Methotrexate - therapeutic use Ointments Pharmacology. Drug treatments Phototherapy Psoriasis - drug therapy Risk Safety Skin, nail, hair, dermoskeleton Treatment Outcome |
| title | Combined topical calcipotriene ointment 0.005% and various systemic therapies in the treatment of plaque-type psoriasis vulgaris : Review of the literature and results of a survey sent to 100 dermatologists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T09%3A35%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20topical%20calcipotriene%20ointment%200.005%25%20and%20various%20systemic%20therapies%20in%20the%20treatment%20of%20plaque-type%20psoriasis%20vulgaris%20:%20Review%20of%20the%20literature%20and%20results%20of%20a%20survey%20sent%20to%20100%20dermatologists&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=KATZ,%20H.%20I&rft.date=1997-09&rft.volume=37&rft.issue=3&rft.spage=S62&rft.epage=S68&rft.pages=S62-S68&rft.issn=0190-9622&rft.eissn=1097-6787&rft.coden=JAADDB&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E9344188%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9344188&rfr_iscdi=true |